

Why Parkinson's disease patients aren't walking tall

July 12 2010

Many of the symptoms of Parkinson disease can be alleviated with drugs that target dopamine, a chemical in the brain that is involved in nerve cell communication and therefore known as a neurotransmitter.

However, such drugs do not improve the gait disorders and falls that commonly affect individuals with severe and advanced forms of Parkinson disease. Understanding which [nerve cells](#) in the [brain](#) are involved in these symptoms of Parkinson disease might provide researchers with new therapeutic targets.

In this context, a team of researchers, led by Chantal François and Etienne Hirsch, at Université Pierre et Marie Curie — Paris 6, France, has now determined that the presence of gait disorders in patients with Parkinson disease and in aged monkeys with Parkinson-like disease was associated with loss of nerve cells that produce the [neurotransmitter](#) acetylcholine in a region of the [brain](#) known as the pedunculopontine nucleus (PPN). Consistent with this, disrupting these nerve cells induced gait and postural deficits in monkeys.

The authors therefore suggest that targeting acetylcholine-producing nerve cells in the PPN might provide a way to alleviate the gait disorders and falls experienced by individuals with Parkinson disease.

More information: View this article in the Journal of Clinical Investigation at: www.jci.org/articles/view/4264...8810b92e3074e99478bd

Provided by Journal of Clinical Investigation

Citation: Why Parkinson's disease patients aren't walking tall (2010, July 12) retrieved 30 April 2024 from <https://medicalxpress.com/news/2010-07-parkinson-disease-patients-tall.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.